Ortivus

Delisting Announcement • Oct 25, 2024

Ortivus is applying to list its shares on the Nasdaq First North Growth Market.

The Board of Directors of Ortivus has decided to apply to Nasdaq to delist the company's shares from Nasdaq Stockholm and, simultaneously, apply for listing on the Nasdaq First North Growth Market.

The company estimates that the process may take up to 30 days.

Following a transfer of listing, the company will continue to publish interim reports quarterly, which, as before, will be prepared in accordance with IFRS with the application of IAS 34. Ortivus has a long history of operating in a public environment and thus communicating transparently with market participants, which the company will, of course, continue to do. The company has appointed FNCA as Certified Adviser.

The Board's decision to apply for a transfer of listing is part of the ongoing process of reviewing and implementing significant cost-saving measures within the Ortivus Group.

The Board assesses that listing the company's shares on the Nasdaq First North Growth Market will reduce costs, both for the exchange itself and for auditing.

Contacts

For further information, please contact

Gustaf Nordenhök, CEO

Telefon +46 8 446 45 00

About Ortivus

Ortivus develops and commercialises MobiMed, e-health and medical technology solutions for a safer and more efficient healthcare. The company was founded in 1985 and is today a leading provider of mobile digital solutions for prehospital care, worldwide. Ortivus' innovations are based on in-depth expertise in cardiology as well as decades of development together with users and customers. The company's headquarters are located in Danderyd, Stockholm. The company has, since 1998, a wholly owned subsidiary based in the United Kingdom and since 2022, a wholly owned subsidiary based in Denmark.

MobiMed is a modular platform that connects and enable real-time information sharing throughout the prehospital care chain. It is currently used by over 12,000 paramedics in over 2,700 emergency vehicles. The platform, MobiMed, consists of several product modules that are completely integrated but can also be used stand-alone. MobiMed comprises four main solutions: MobiMed Monitor, that measures, monitors and shares patients' vital parameters and ECG in realtime, MobiMed ePR, - an electronic patient record for decision support, collection of patient data and clinical documentation, MobiMed enRoute, - a tool for navigation and case management, and MobiMed Life - a range of stand-alone defibrillators.

MobiMed saves vital seconds and enable healthcare professionals make the right decisions in critical situations. MobiMed also contributes to improved quality of care and saved resources.

Ortivus Class A and Class B shares are listed on the NASDAQ Stockholm Small Cap list.

Read more about Ortivus at www.ortivus.com

This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-25 14:25 CEST.

Attachments

Ortivus is applying to list its shares on the Nasdaq First North Growth Market.